Fexagratinib - Abbisko Therapeutics
Alternative Names: ABSK-091; AZD-4547Latest Information Update: 16 Jul 2025
At a glance
- Originator AstraZeneca
- Developer Abbisko Therapeutics; AstraZeneca; Dust Diseases Authority; Institute of Respiratory Health; National Cancer Institute (USA); University of Glasgow; University of Leeds; University of Wisconsin-Madison
- Class Antineoplastics; Benzamides; Phenyl ethers; Piperazines; Pyrazoles; Small molecules
- Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Lymphoma; Multiple myeloma; Solid tumours; Urogenital cancer
- Preclinical Skin cancer
- No development reported Liver cancer
- Discontinued Bladder cancer; Breast cancer; Glioblastoma; Head and neck cancer; Lung cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer
Most Recent Events
- 13 Feb 2025 Efficacy and adverse events data from a phase II trial in Urothelial carcinoma presented at the 2025 Genitourinary Cancers Symposium (ASCO-GeCS-2025)
- 13 Feb 2025 Efficacy, and adverse events data from phase I/II trial in Urogenital cancer presented at the Genitourinary Cancers Symposium (ASCO-GU-2025)
- 13 Sep 2024 Pharmacodynamics data from the preclinical studies in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)